Gamida Cell Ltd
GMDA.O- Latest Trade
- trading lower1.74USD
- Change
- -0.03
- % Change
1.69%Negative
- Day Range
- 1.69 - 1.80
- 52-Week Range
- 1.67 - 6.60
As of Jul 2 2022. Values delayed up to 15 minutes
- Previous Close
- 1.77
- Open
- 1.75
- Volume
- 323,713.00
- 3 Month Average Trading Volume
- 15.01
- Shares Out (Mil)
- 59.98
- Market Cap
- 103.77
- Forward P/E
- -1.46
- Dividend Yield
- -99,999.99
Key Statistics
1.83333333 mean rating - 6 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- -99,999.99
- Price To Book (Quarterly)
- 4.15
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 286.61
- Long Term Debt/Equity (Quarterly)
- 286.61
- Return On Investment (TTM)
- -63.39
- Return On Equity (TTM)
- -55.65
2021 (millions USD)
About Gamida Cell Ltd
Company Information
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. The following are the Company's clinical pipeline products: NiCord, which is evaluated in a Phase III study in patients with high-risk blood cancers as well as in a Phase SS study in patients with severe aplastic anemia, as well as NAM-NK, an innate immunotherapy for the treatment of hematologic and solid tumors, which is investigated in a Phase I investigator-sponsored trial for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL), and multiple myeloma (MM).
Address
PO Box 34670JERUSALEM,
91340
Israel
Industry
Biotechnology & Drugs
Executive Leadership
- Robert I. Blum
- Non-Executive Independent Chairman of the Board
- Julian Adams
- Chief Executive Officer, Director
- Shai Lankry
- Chief Financial Officer
- Michele Korfin
- Chief Operating Officer, Chief Compliance Officer
- Tracey Lodie
- Chief Scientific Officer
- Joshua D. Hamermesh
- Chief Business Officer
- Ronit Simantov
- Chief Medical Officer
- Jas Uppal
- Chief Regulatory, Quality Officer
- Ivan Borrello
- Director
- Anat Cohen-Dayag
- Director
- Naama Halevi-Davidov
- Director
- Stephen T. Wills
- Independent Director
- Nurit Benjamini
- Non-Executive Independent Director
- David Fox
- Non-Executive Independent Director
- Kenneth I. Moch
- Non-Executive Independent Director
- Michael S. Perry
- Non-Executive Independent Director
- Shawn Cline Tomasello
- Non-Executive Independent Director
Latest News
- MarketsChipotle, Zosano, CVS, Omnicom
Wall Street's main indexes rallied on Wednesday, with high-growth stocks gaining as a recent rally in Treasury yields paused, while investors took comfort from upbeat earnings reports and signs of easing tensions in Ukraine.
- MarketsChipotle, Enphase Energy, Omnicom, CVS
Wall Street's main indexes rose on Wednesday, with high-growth stocks gaining as a recent rally in Treasury yields paused, while investors took comfort from upbeat earnings reports and signs of easing tensions in Ukraine.
- MarketsFord, Splash Beverage, semiconductor stocks, U.S. Bancorp
The Nasdaq index tumbled on Wednesday, on track to confirm a correction as it briefly shed more than 10% from its record closing high on Nov. 19.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,806.10 | 0.11%Positive |
| Copper | 679.40 | 2.12%Negative |
| Brent Crude Oil | 111.63 | -- |
| CBOT Soybeans | 1,622.00 | 3.16%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,825.33 | 1.06%Positive |
| Euro STOXX 50 | 3,448.31 | 0.19%Negative |
| FTSE 100 | 7,168.65 | 0.01%Negative |
| Nikkei 225 | 25,935.62 | 1.73%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes